St. Vincent to dangle health insurance deal to employers
The hospital system and a partner company have started meeting with health insurance brokers to pitch a program to save employers money by keeping workers and their families healthier.
The hospital system and a partner company have started meeting with health insurance brokers to pitch a program to save employers money by keeping workers and their families healthier.
Gov. Mike Pence has directed the Indiana Department of Health to investigate whether organs from aborted fetuses are being sold.
Immunocore Ltd., which this week achieved the biggest private fundraising by a European biotechnology firm in 10 years, plans to accelerate development of its cancer therapy using the money and seek expedited approval.
When you have a health care business for which “there’s a tremendous need and virtually no product”—which Mainstreet founder and CEO Zeke Turner said is what his company has—growth potential would seem unlimited.
State enrollment in HIP 2.0 has climbed to nearly 290,000 participants, with about 60 percent of those people under age 40, according to state figures presented Thursday.
Indianapolis-based Eli Lilly and Co. and Acrux DDS Pty Ltd. have filed a lawsuit against Lupin Pharmaceuticals Inc. for alleged infringement of patents that cover the testosterone treatment Axiron.
The drug, known as necitumumab, improved patients’ overall chances of survival, yet people taking the medicine also experienced more risk, Food and Drug Administration staff said in a report Tuesday.
With Aetna Inc. and Humana Inc. agreeing to a $37 billion merger, pressure is mounting on the other major health insurers, including Cigna Corp. and Anthem Inc., to make their own deals.
Aetna Inc. agreed to buy Humana Inc., the second-largest provider of private Medicare insurance, for $37 billion in cash and stock to broaden its health-care coverage.
Michael A. Byers’ Tooth Bank is one of a tiny group of U.S. companies catering to the latest iteration of stem cell therapy: harvesting stem cells from the pulp inside baby teeth and extracted wisdom teeth, then culturing, freezing and storing them at a cryostorage facility for later use.
Patients from around the country have filed 100 lawsuits against Bloomington-based Cook, alleging that some of its blood-clot filters have broken apart, moved or poked through the blood vessel where they are implanted.
The Indianapolis-based hospital system has agreed to pay $20.3 million to settle claims that it overbilled the Medicare and Medicaid programs.
Anthem Inc.’s proposed $47 billion buyout of Cigna Corp. is the latest example of corporate deals that get hung up over executive egos and turf battles. For example, Anthem CEO Joe Swedish wants to lead the merged firm, to the chagrin of Cigna’s CEO.
Wellness company On Target Health LLC, which one year ago launched a program to help overweight workers lose fat but not muscle, is seeing strong results from its first two clients.
Eli Lilly and Co. received some European legal backing for its top product, the lung cancer treatment Alimta, on Thursday when a British court upheld a patent protecting a vitamin regimen administered with the drug.
Eli Lilly and Co. has been ordered to face claims it misled consumers about “brain zaps” and other withdrawal side effects tied to its antidepressant Cymbalta in the first cases slated to be heard by juries.
The Indiana-based company has taken the name Zimmer Biomet Holdings Inc. and will trade under the ticker symbol to "ZBH" on Monday. Zimmer Holdings Inc. agreed to buy privately-held Biomet in April 2014.
About 160,000 low- and moderate-income Indiana residents could lose health insurance premium subsidies provided under the Affordable Care Act if the U.S. Supreme Court rules them illegal, two groups estimated Tuesday.
In a new scoring system for oncology drugs, a leading group of U.S. cancer doctors awarded a zero for overall benefit to a regimen featuring Alimta, Eli Lilly and Co.’s top-selling product.
After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.